

# SecureEMR version 5.0 Real World Testing Plan CY2023 Results

---

## End-user engagement and effectiveness of the E- Prescribing

Developer Name:	Inmediata Health Group
Product Name:	SecureEMR
Version Number:	5.0
CHPL ID:	15.07.04.2769.SE01.05.01.1.221228
RWT Page URL:	<a href="https://portal.inmediata.com/emr/#rwt">https://portal.inmediata.com/emr/#rwt</a>



## Testing Plan

### Justification for Real World Testing Approach

Inmediata Health Group will be conducting a Real World Testing using SecureEMR 5.0 to measure the end-user engagement and effectiveness of the E-Prescribing [criteria 170.315(b)(3)] module of our EHR.

E-Prescribing is a very important module to our end-users and their patients since it simplifies the process for fulfilling and renewing prescriptions.

Our approach is to use deidentified analytics reports to measure the use of electronic prescriptions transactions (new prescriptions and refill requests) from our providers.

We will also measure the error rate for the transactions submitted to our e-prescriptions clearinghouse to demonstrate our compliance with NCPDP Standard V2017071.

### Standards Updates (SVAP and USCDI)

NCPDP Standard V2017071

### Care Setting

Ambulatory

## Overall Expected Outcome

- Real World Testing will show a high rate of usage in the prescription module with our providers in comparison to those users that are not using this module
- Real World Testing will show a higher rate of electronic prescriptions in comparison to those prescriptions sent by fax to the pharmacies
- Real World Testing will show a low rate of errors from our prescription hub

## Measures Used

### Measure #1

- **Certification Criteria:**

170.315(b)(3) E-Prescribing

- **Justification**

E-Prescribing is a very important module to our end-users and their patients since it simplifies the process for fulfilling and renewing prescriptions.

- **Test Methodology**

Our approach is to use deidentified analytics reports to measure the use of electronic prescriptions transactions (new prescriptions and refill requests) from our providers.

We will also measure the error rate for the transactions submitted to our e-prescriptions clearinghouse to demonstrate our compliance with NCPDP Standard V2017071.

- **Relied upon software**

Our application relays on **Surescripts** as our e-prescription hub and **First Data Bank MedKnowledge** as our medications database to meet criteria 170.315(b)(3) E-Prescribing. We will analyze the responses from Surescripts to measure the error rate for our providers using electronic prescriptions. At this time, the real-world testing will not be considering specific medications from the FDB data source.

- **Expected Outcome**

1. Real World Testing will show a high rate of usage in the prescription module with our providers in comparison to those users that are not using this module
2. Real World Testing will show a higher rate of electronic prescriptions in comparison to those prescriptions sent by fax to the pharmacies
3. Real World Testing will show a low rate of errors from our prescription hub

This Real World Testing plan is complete with all required elements, including measures that address all certification criteria and care settings. All information in this plan is up to date and fully addresses the health IT developer's Real World Testing requirements.

## Real World Test Results

The dataset used for this analysis the production prescription data from January 1<sup>st</sup> of 2022 until December 31<sup>st</sup> of 2022.

### 1. Real World Testing will show a high rate of usage in the prescription module with our providers in comparison to those users that are not using this module

**Result:** 29.86%

**Conclusion:** The results are showing that not all our providers are prescribing in all patient encounters since for all the visits documented during 2022, only 29.86% had, at least, one prescription created in the system.

### 2. Real World Testing will show a higher rate of electronic prescriptions in comparison to those prescriptions sent by fax to the pharmacies

**Result:** 68.60%

**Conclusion:** The results confirm that most of the prescription created in the system were electronically transmitted using our e-Prescription hub in comparison with those printed or faxed.

### 3. Real World Testing will show a low rate of errors from our prescription hub

**Result:** 2.51%

**Conclusion:** It has been confirmed that the number of errors/rejections from our prescription hub is very low.



636 Avenida San Patricio  
Third Floor, San Juan PR 00920  
Tel. 787-774-0606  
[www.inmediata.com](http://www.inmediata.com)

**Authorized Representative Name:** Camilo Torres

**Authorized Representative Email:** [ctorres@inmediata.com](mailto:ctorres@inmediata.com)

**Authorized Representative Phone:** 787-783-3233

**Authorized Representative Signature:** *Camilo Torres*

**Date:** 01/27/2023